Research Article
The Efficacy of Transarterial Chemoembolization plus Apatinib or Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
Table 3
Adverse events of patients after receiving TACE-S and TACE-A before PSM.
| | Adverse events | All grades | Grades ≥3 | | TACE-S | TACE-A | value | TACE-S | TACE-A | value |
| | Fever | 23 (42.6) | 73 (52.5) | 0.216 | 1 (1.9) | 2 (3.7) | >0.999 | | Abdominal pain | 44 (81.5) | 112 (80.6) | 0.886 | 2 (3.7) | 5 (3.6) | 0.972 | | Nausea | 35 (64.8) | 98 (70.5) | 0.443 | 1 (1.9) | 4 (2.9) | 0.677 | | Vomiting | 24 (44.4) | 75 (54) | 0.235 | 1 (1.9) | 3 (2.2) | 0.892 | | Anorexia | 22 (40.7) | 61 (46.1) | 0.692 | 0 (0) | 0 (0) | >0.999 | | Diarrhea | 12 (22.2) | 28 (20.1) | 0.749 | 0 (0) | 0 (0) | >0.999 | | Hypertension | 19 (35.2) | 68 (48.9) | 0.085 | 1 (1.9) | 2 (1.4) | >0.999 | | Fatigue | 6 (11.1) | 23 (16.5) | 0.343 | 0 (0) | 0 (0) | >0.999 | | Hand-foot skin reaction | 7 (13.0) | 21 (15.1) | 0.704 | 2 (3.7) | 5 (3.6) | 0.687 | | Gastrointestinal hemorrhage | 0 (0) | 2 (1.4) | >0.999 | 0 (0) | 0 (0) | >0.999 | | Headache | 9 (16.7) | 24 (17.3) | 0.921 | 0 (0) | 1 (0.7) | >0.999 | | Proteinuria | 1 (1.9) | 3 (2.2) | 0.892 | 0 (0) | 0 (0) | >0.999 |
|
|
Abbreviations: TACE-S: transarterial chemoembolization combined with sorafenib; TACE-A: transarterial chemoembolization combined with apatinib.
|
